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Outcome of HIV-infected patients with AIDS-related lymphomashas improved during recent years. However, data on incidence,risk factors, and outcome of relapses in AIDS-related lym-
phomas after achieving complete remission are still limited. This
prospective observational multicenter study includes HIV-infected
patients with biopsy- or cytology-proven malignant lymphomas since
2005. Data on HIV infection and lymphoma characteristics, treatment
and outcome were recorded. For this analysis, AIDS-related lymphomas
patients in complete remission were analyzed in terms of their relapse-
free survival and potential risk factors for relapses. In total, 254 of 399
(63.7%) patients with AIDS-related lymphomas reached a complete
remission with their first-line chemotherapy. After a median follow up
of 4.6 years, 5-year overall survival of the 254 patients was 87.8%
(Standard Error 3.1%). Twenty-nine patients relapsed (11.4%). Several
factors were independently associated with a higher relapse rate, includ-
ing an unclassifiable histology, a stage III or IV according to the Ann
Arbor Staging System, no concomitant combined antiretroviral therapy
during chemotherapy and R-CHOP-based compared to more intensive
chemotherapy regimens in Burkitt lymphomas. In conclusion, complete
remission and relapse rates observed in our study are similar to those
reported in HIV-negative non-Hodgkin lymphomas. These data provide
further evidence for the use of concomitant combined antiretroviral ther-
apy during chemotherapy and a benefit from more intensive chemother-
apy regimens in Burkitt lymphomas. Modifications to the chemotherapy
regimen appear to have only a limited impact on relapse rate.     
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ABSTRACT
Introduction
Over the last two decades, the incidence of AIDS-relat-
ed lymphomas (ARL) has markedly declined due to the
introduction of combination antiretroviral therapy
(cART). However, ARL remain a major cause of morbidity
and mortality, and represent the highest proportion of all
AIDS-related deaths.1 Patients with ARL are usually treat-
ed with the same chemotherapy protocols established in
the HIV-negative setting,2 and the rates of complete remis-
sion (CR) achieved are comparable to those reported in
their HIV-negative counterparts.3,4 However, available data
on the incidence and potential risk factors of recurrent dis-
ease in ARL are scarce, and treatment of disease relapse
remains challenging.4,5 In recent studies on HIV-negative
patients with diffuse large B-cell lymphoma (DLBCL), R-
CHOP-based regimens (rituximab, cyclophosphamide,
adriamycin, vincristine, and prednisone) resulted in CR
rates of around 65-80%. Differences in response rates
largely depend on the pre-treatment International
Prognostic Index (IPI) for aggressive lymphomas.6,7 In
patients who had achieved a CR, relapse rates ranged
from 6-10%.6,8 The second most common ARL are Burkitt
or Burkitt-like lymphomas (BL).9,10 In the HIV-negative set-
ting, CR and overall survival (OS) rates of around 80-90%
were reported by different groups.10-12 In a large prospec-
tive trial on short-intensive chemotherapy combined with
rituximab for patients with BL, the relapse rate was 12%.10
Although this approach also proved feasible in HIV-relat-
ed BL,9 it remains unclear whether relapse rates reported
in HIV-negative DLBCL and BL are different to those in
ARL. Thus, we investigated the risk factors and incidence
of relapse in a large cohort of ARL patients who had
achieved a CR after first-line treatment.
Methods
Study design
The German HIV Lymphoma Cohort is an ongoing, prospective
observational multicenter study including all adult HIV infected
patients who are diagnosed with biopsy- or cytology-proven
malignant lymphoma in 33 participating centers since January
2005. Data on HIV-infection and lymphoma characteristics, treat-
ment and outcome are recorded. From the time of lymphoma
diagnosis, patients are followed every six months. Ethics approval
was obtained from the ethics committees of the University of
Cologne (IRC Cologne: 05-174), Germany, and written informed
consent was given by each participating patient.
The present analysis includes only patients with aggressive B-
cell lymphoma in first CR. Lymphomas were grouped in DLBCL,
BL, plasmablastic lymphoma (PBL) and ARL, not further classifi-
able, the latter group representing aggressive B-cell non-Hodgkin
lymphomas (B-NHL) that could not be classified into any subtype.
To study the impact of chemotherapy dose intensity on the risk of
relapse in patients treated with either R-CHOP-based regimens or
the short intensive GMALL protocol,10 we performed an analysis
of dose reductions and delays in chemotherapy cycles.
(Information about the GMALL and R-CHOP protocol can be
found in the Online Supplementary Tables S1 and S2, respectively).
A full-intensity treatment was considered to consist of six cycles
of chemotherapy according to the R-CHOP or GMALL protocol
administered at 3-week intervals without dose reductions and
within a period of 120 days (5x21 days for 6 cycles plus a maxi-
mum of 3 days delay per cycle). Less than 6 cycles of chemother-
apy were classified as “cycle reduction” and the treatment dura-
tion was calculated according to the number of cycles given. If the
dose of any chemotherapy drug was reduced by 20% or more,
treatment intensity was considered to be reduced. 
As positron emission tomography (PET) scans were not routine-
ly performed, the 1999 standardized response criteria for non-
Hodgkin’s lymphomas13 were used rather than the 2007 criteria.14
CR was defined as the disappearance of all disease manifestations
for at least three months. This definition also includes uncertain
complete remission (CRu) that implied a residual mass of 1.5 cm
or smaller that remained unchanged over at least three months. 
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics
software (IBM, Armonk, NY, USA), v.24.0. Univariate statistics
were performed using Pearson’s χ², Fisher’s exact one-way
Analysis of Variance (ANOVA) with Bonferroni-corrected post-
hoc test, or Kruskal-Wallis test depending on data. For the multi-
variate Cox regression analysis, continuous clinically meaningful
breakpoints that showed P-values below 0.1 in the univariate
analysis were considered. Kaplan-Meier curves were used to illus-
trate the relapse-free survival (RFS) and overall survival.
Differences between subgroups were assessed with the log-rank
test. RFS was defined as the period between first diagnosis and
any lymphoma relapse according to the STEEP criteria.15 OS was
defined as the period between first diagnosis and death from any
cause. All-cause deaths as well as “lost to follow up” were cen-
sored. All P-values were two-sided. P<0.05 was considered statis-
tically significant.
Results
Patients' characteristics and outcome
Numbers and characteristics of patients included in the
present analysis are depicted in Figure 1. In total, 254 of
399 (63.7%) patients with high-grade NHL of B-cell origin
(classified as ARL) reached a CR with their first-line
chemotherapy. Of those, 127 had DLBCL, 91 BL, 29 PBL,
and 7 ARL, not further classified. ARL was CD20-negative
in 24 of 254 cases (9.5%), among them 22 PBL and 2
DLBCL cases. Among 22 PBL cases with information on
Epstein-Barr-Virus (EBV) status, EBV was present in 15
(68%). Overall, 86.2% of patients with CD20+ lym-
phomas received rituximab. Notably, patients diagnosed
before 2010 were less frequently treated with rituximab
than those diagnosed from 2010 onwards (79% vs. 96%,
P<0.001). Further, 73% of patients with CD4 cell counts
less than 50/µl received rituximab compared to 88% with
CD4 counts 50/mL or over (P=0.096). Patients' character-
istics with respect to treatment outcomes are listed in
Table 1. OS of patients who achieved CR with first-line
therapy was significantly better than that of patients in
other response groups (Figure 2). After a median follow up
of 4.6 years, 5-year OS of the entire group of all 262
patients in first CR was 87.1% [standard error (SE) 2.3%]
(Figure 3A) with differences between lymphoma sub-
types: 87.8% (SE 3.1%) in DLBCL, 87.6% (SE 3.7%) in BL,
79.6% (SE 11.3%) in PBL, and 83.3% (SE 15.2%) in ARL,
not further classified (P=0.994) (Figure 3B). 
Incidence of recurrent disease in ARL
After a median follow up of 4.6 years, a relapse of the
ARL had occurred in 29 of 254 patients (11.4%). Relapses
were observed in 14 patients with DLBCL (11.0%), 9 with
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BL (9.9 %), 3 with PBL (11.5%) and 3 with ARL, not fur-
ther classified (42.9%), after a median follow up of 5.0,
4.6, 3.5 and 6.0 years, respectively. Isolated central nerv-
ous system (CNS) relapses were observed in 3 of 29
patients (DLBCL: n=2; BL: n=1). RFS depicted by Kaplan
Meier curves is shown in Figure 3C and D. Five-year RFS
(5yRFS) was 88.4% (SE 2.9%) in DLBCL, 88.9% (SE 3.5%)
in BL, and 88.6% (SE 6.2%) in PBL. By contrast, 5yRFS
was lower in patients with ARL, not further classified
[57.1% (SE 18.7%); P=0.057) (Figure 3D). 
Among patients who achieved CR with first-line R-
CHOP-based protocols, 5yRFS was 87.8% (SE 3.1%) and
84.4% (SE 8.3%) in DLBCL and PBL, respectively, as com-
pared to 65.5% (SE 12.6) in BL and 40.0% in ARL, not fur-
ther classified (SE 21.9%; P=0.005) (Figure 3E). No signifi-
cant differences in 5yRFS between ARL subtypes were
observed in patients treated with the GMALL protocol
(P=0.884) (Figure 3F), although the number of patients
with subtypes other than BL was very small in this analy-
sis. Of note, patients with BL who received the GMALL
protocol had a significantly better 5yRFS than those
receiving R-CHOP-based protocols [94.2% (SE 2.8%) vs.
65.5% (SE 12.6%); P=0.001].
Risk factors for recurrent disease in ARL
Univariate analysis identified several factors associated
with a lower risk for ARL relapse such as a low IPI, stage
I or II according to the Ann Arbor Staging System, cART
given during chemotherapy, CD4 T-cell counts
>200x109/L, pathology other than ARL, not further classi-
fied, and chemotherapy according to the GMALL-proto-
col (Table 2). These factors were analyzed in a multivari-
ate Cox proportional hazards model, with backward step-
wise elimination based on a Wald statistic with P≤0.1.
Relapses in AIDS-related lymphomas
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Figure 1. Flow chart of patients included in the present analysis. NHL: non-
Hodgkin lymphoma; T-NHL: T-cell non-Hodgkin lymphoma; CR: complete remis-
sion; BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; PBL: plas-
mablastic lymphoma; ARL: AIDS-related lymphoma.
After two elimination steps, histology [BL: Hazard ratio
(HR) 2.60 95% Confidence Interval (95%CI): 0.92 – 7.4,
PBL: HR 1.28 95% CI 0.36-4.57, ARL, not further classi-
fied: HR 5.08 95% CI 1.13 – 22.90, indicator = DLBCL),
stage III or IV according to the Ann Arbor Staging System
(HR 4.85 95%CI 1.44 – 16.34), no concomitant cART (HR
4.28 95%CI 1.19 – 15.39) and use of R-CHOP (HR: 7.59
95%CI 1.87 – 30.81) remained in the model (Table 2). A
higher IPI was no longer predictive anymore in the multi-
variate model.
Dose intensity of chemotherapy
Since chemotherapy regimen (R-CHOP or GMALL)
seems to be critical for RFS, we investigated how many
patients of all aggressive B-NHL had any kind of reduc-
tion (either in the number of chemotherapy cycles or in
the treatment intensity) or a delay during their treatment.
Results of dose intensity analysis are shown in Online
Supplementary Table S3. Overall, 32.7% of the patients
had a treatment delay, 13.8% had dose reductions, and
16.5% had reduced numbers of chemotherapy cycles
P. Schommers et al.
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Table 1. Patients’ characteristics based on their treatment outcome. 
CR after CR after Progressive Partial On Treatment No Total P
first-line further lines disease remission chemotherapy related chemotherapy (N=387)
chemotherapy chemotherapy (n=45) (n=22) (n=15) deaths given
(n=254) (n=21) (n=23) (n=7)
Median age (years) 44 48 45 44 50 48 46 45 0.104b
Male 230 (91%) 20 (95%) 44 (98%) 21 (96%) 15 (100%) 21 (91%) 6 (86%) 357 (92%) 0.514a
Median viral load 19031 26790 40208 7159 11387 2390 105000 18557 0.784b
(copies/mL)
HIV-RNA below limit of detection 74 (30%) 5 (24%) 11 (25%) 8 ((36%) 4 (29%) 8 (35%) 2 (29%) 112 (30%) 0.903a
Median CD4+ 248 190 111 186 153 157 58 212 0.006b
T cells (x109/L)
CD20+ lymphoma 213 (90%) 20 (95%) 34 (81%) 18 (90%) 10 (83%) 13 (68%) 4 (67%) 312 (87%) 0.044a
BM involvement 47 (20%) 7 (33%) 15 (39%) 6 (29%) 3 (21%) 6 (21%) 1(17%) 85 (23%) 0.190a
CNS involvement 17 (8%) 2 (10%) 8 (21%) 2 (11%) 1 (9%) 5 (33%) 0 (0%) 36 (11%) 0.023
IPI score
Low 100 (42%) 5 (24%) 8 (18%) 2 (11%) 5 (39%) 2 (9%) 0 (0%) 122 (36%)
Intermediate 104 (44%) 11 (52%) 20 (46%) 13 (68%) 6 (42%) 11 (50%) 3 (43%) 168 (46%)
High 34 (14%) 5 (24%) 16 (36%) 4 (21%) 2 (15%) 9 (41%) 4 (57%) 74 (20%) <0.001a
Lymphoma subtype
DLBCL 127 (50%) 7 (33%) 24 (53%) 13 (59%) 7 (47%) 7 (30%) 4 (57%) 189 (49%)
BL 91 (36%) 11 (52%) 12 (27%) 5 (23%) 4 (27%) 9 (39%) 1 (14%) 133 (34%)
PBL 29 (11%) 3 (14%) 7 (16%) 3 (14%) 3 (20%) 7 (30%) 2 (29%) 54 (14%)
ARL, not further classifiable 7 (3%) 0 (0%) 2 (4%) 1 (5%) 1 (7%) 0 (0%) 0 (0%) 11 (3%) 0.420a
Median follow up (years) 4.64 5.4 0.5 0.7 0.1 0.2 0 2.4 <0.001b
BL: Burkitt lymphoma; DLBCL: diffuse large B-cell lymphoma; PBL: plasmablastic lymphoma; IPI: International Prognostic Index; BM: bone marrow; CNS: central nervous sys-
tem. aTwo-sided Pearson’s χ2. bKruskal-Wallis test.
Figure 2. Kaplan-Meier estimates for overall survival (OS) of the differ-
ent observed treatment outcomes of aggressive non-Hodgkin lym-
phomas. CR: complete remission; Prog. Disease: progressive disease;
Part. Remission: partial remission. Dotted line indicates 3 months.
given. Only 37.0% of patients received their full planned
course of therapy. 
Patients who experienced treatment delays and/or dose
reductions or received a reduced number of chemotherapy
cycles were significantly older (42 vs. 45 years; P=0.042)
and had received the GMALL-protocol significantly more
often than patients who completed the full planned course
of therapy (P=<0.001) (Online Supplementary Table S3).
Overall, 86.2% of patients with CD20+ lymphomas
received rituximab. There was no difference in the relapse
rate between patients with or without administration of
rituximab (P=0.75), and our results remained consistent
when patients without rituximab were excluded (data not
shown).
Factors influencing the RFS
To investigate the influence of different factors, includ-
ing treatment reduction or delay on 5yRFS, we investigat-
Relapses in AIDS-related lymphomas
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Table 2. Risk factors for 5-year relapse-free survival (including all aggressive non-Hodgkin lymphoma in first complete remission; n=254).
Aggressive 
NHL (N=254)
5-year relapse-free P P
survival % (univariate) (multivariate)
Sex Male (n=230) 87
Female (n=24) 96 0.229
Age >60Y (n=24) 77
<60Y (n=228) 89 0.178
CNS involvement Yes (n=17) 82
No (n=204) 90 0.305
BM involvement Yes (n=47) 81
No (n=193) 90 0.101 
Bulky Disease Yes (n=44) 86
No (n=137) 88 0.637
CD4+ T cells <50x109/l Yes (n=37) 86
No (n=202) 88 0.573
Prior AIDS-defining illness Yes (n=56) 87
No (n=193) 88 0797
IPI score Low (n=100) 95 Indicator
Intermediate (n=104) 84 0.760
High (n=34) 82 0.039 0.853
Ann Arbor stage I/II (n=93) 95
III/IV (n=156) 83 0.005 0.011
Extranodal involvement Yes (n=71) 87
No (n=181) 88 0.936
ECOG score 0-1 (n=159) 89
2-5 (n=78) 86 0.635
Elevated LDH Yes (n=146) 86
No (n=96) 92 0.143
Antiretroviral Treatment Viral load b.d. (n=74) 88
Naive (n=134) 88
Therapy failure (n=39) 87 0.986
cART during Chemotherapy Yes (n=234) 89
No (n=9) 67 0.033 0.026
CD20 positive lymphoma Positive (n=213) 88
Negative (n=24) 87 0.888
Lymphoma subtype DLBCL (n=127) 88 Indicator
BL (n=91) 89 0.072
PBL (n=29) 89 0.703
ARL, not further classifiable (n=7) 57 0.064 0.034
Chemotherapy CHOP (n=163) 84
GMALL (n=87) 95 0.013 0.005
Univariate statistics: Log rank test. Multivariate statistics: Cox regression. Viral load b.d.: Viral load below limit of detection; cART: combination antiretroviral therapy; BL: Burkitt
lymphoma; DLBCL: diffuse large B-cell lymphoma; PBL: plasmablastic lymphoma; IPI: International Prognostic Index; BM: bone marrow; CNS: central nervous system; ECOG:
Eastern Cooperative Oncology Group scale. 
ed two selected groups: patients with DLBCL receiving R-
CHOP-based regimens and patients with BL receiving the
GMALL-regimen (see also Figure 1). In patients with
DLBCL who received a R-CHOP-based treatment, a high
IPI, an elevated LDH, stage III or IV according to the Ann
Arbor Staging System, and bone marrow involvement at
first diagnosis were associated with a significantly
increased risk of relapse (Online Supplementary Table S4).
However, none of these parameters turned out to be an
independent risk factor in the Cox proportional hazards
model. Of note, chemotherapy dose reductions, treatment
delays or a reduced number of R-CHOP-cycles given did
not adversely affect 5yRFS (Online Supplementary Table S4). 
By univariate analysis, patients with BL who underwent
GMALL-chemotherapy had a significantly increased risk
of relapse if the following factors were present: diagnosis
of another AIDS-defining disease prior to BL diagnosis,
CNS-involvement, failure of cART defined as measurable
viral loads despite concomitant cART, concomitant cART
during chemotherapy, and reduced numbers of
chemotherapy cycles administered (Online Supplementary
Table S4). However, none of these factors remained signif-
icant in the Cox proportional hazards model. 
Discussion
In this large prospective cohort study of 254 ARL
patients who had achieved a CR with first-line
chemotherapy (64% of all cases), the total relapse rate was
11% after a median follow up of 4.6 years. Patients with
DLBCL who were mainly treated with R-CHOP-based
regimens had a relapse rate of 11%. These rates are in line
with the 6-10% relapse rates reported in HIV-negative
DLBCL in first CR.6,8 Notably, the 10% relapse rate of
patients with BL who were mainly treated with the
GMALL protocol compares favorably with the 12%
relapse rate reported in the HIV-negative setting.10 
Outcome of patients with ARL in which histology was
not further classifiable was poor with a 5yRFS of only
57%. There was no difference in type and intensity of
chemotherapy to that used in DLBCL (data not shown),
therefore these cases may represent a subgroup of highly
aggressive lymphomas that may benefit from intensive
chemotherapy regimens. 
Even though the overall survival of patients with PBL
was shown to be significantly worse than that in DLBCL
and BL,16,17 there was no difference in relapse rates
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Figure 3. Kaplan-Meier estimates for aggressive non-Hodgkin lymphoma (NHL) that achieved complete remission (CR) after first-line chemotherapy. (A) Overall
survival of all AIDS-related lymphomas (ARL) and of (B) different subtypes (Log rank test: P=0.982). (C) Relapse-free survival of all ARL and of (D) different subtypes
(P=0.064). (E) Relapse-free survival of different subtypes treated with R-CHOP-based regimens (rituximab, cyclophosphamide, adriamycin, vincristine, and pred-
nisone) and (F) GMALL-based chemotherapeutic regimens (P=0.006 and P=0.79, respectively). DLBCL: diffuse-large B-cell lymphoma; BL: Burkitt-lymphoma; PBL:
plasmablastic lymphoma. Dotted line indicates 3 months.
A
C
E
B
D
F
between patients who have achieved a CR (12%)  to those
observed in DLBCL and BL. The inferior OS of the small
patient group of PBL may at least in part be explained by
3 late deaths 4-7 years after first diagnosis that were unre-
lated to lymphoma: one case of sepsis due to pneumonia
and 2 cases of secondary malignancies (lung cancer and
oral cavity cancer). 
AIDS-related lymphoma patients with an intermediate
and high IPI had higher relapse rates and a lower 5yRFS
than those with a low IPI in univariate analysis. The lack
of significance in the multivariate analysis was somewhat
surprising as previous studies have demonstrated strong
prognostic relevance of the IPI in ARL.17,18 Whether
patients with HIV-related DLBCL and intermediate or
high IPI may benefit from more intensive treatments such
as the CHOEP regimen, as has been shown in the HIV-
negative setting, remains to be seen.19,20
Previous studies have shown that concomitant cART
was associated with improved CR rates and a trend
toward improved OS.21 Our results also support a concur-
rent use of cART as it was associated with better 5yRFS.
Several cART regimens with a good safety and tolerability
profile and low interaction potential are now available,
strongly arguing for a simultaneous cART during ARL
chemotherapy.4
The use of R-CHOP-based regimens showed signifi-
cantly less treatment delays and reductions, as compared
to the GMALL protocol. However, the majority of
patients with BL (84%) received chemotherapy according
to the GMALL-protocol which resulted in significantly
lower relapse rates compared to R-CHOP-based regimens
(Figure 3E and F). Notably, treatment delays and a reduced
chemotherapy intensity appeared to have no impact on
the relapse-rate in GMALL-treated BL, while, at least in
the univariate analysis, a reduced number of chemothera-
py cycles was associated with lower 5yRFS. Thus, our
data indicate that HIV-infected patients with BL should be
treated with the planned number of intensive chemother-
apy cycles.3,8 By contrast, reduced relative dose intensity
did not negatively impact 5yRFS in patients treated with
R-CHOP-based regimens for DLBCL. This finding does
not correspond to data reported in HIV-negative DLBCL
and warrants further investigation.22,23
It is important to note that this analysis focuses on
patients in first CR, and that factors that predict RFS were
not necessarily associated with initial treatment response.
Our study has several limitations. First, given the uncon-
trolled design selection biases cannot be ruled out. Second,
the analysis of risk factors associated with outcome is
more exploratory in nature. Given the relatively low num-
ber of patients in some of the selected subgroups, the sta-
tistical power of the analysis is limited and does not allow
any firm conclusions to be drawn. Notably, data on poten-
tial risk factors for lymphoma relapse such as adherence to
ART or cumulative viremia between CR and relapse are
not available.24 Nevertheless, if a CR has been reached, the
relapse rate was low regardless of whether the CR was
achieved with or without dose reduction and whether rit-
uximab was used or not. Fourth, CRs were not generally
confirmed by negative positron emission tomography
(PET) scans as recommended by current guidelines for
HIV-negative lymphomas.14,25 However, the role of PET-
scanning in HIV-lymphoma remains controversial as the
rate of false positive results appears to be higher than in
the HIV-negative setting.26,27 Finally, the number of
patients with ARL, not further classified, may have been
lowered by reference pathology services which, in turn,
may have slightly altered our findings.
In conclusion, both CR rates and relapse rates observed
in the German HIV-related Lymphoma Cohort Study are
similar to those reported in HIV-negative NHL. These data
add to the growing body of evidence showing that treat-
ment outcomes compare favorably with those in patients
with NHL and no HIV infection.
Relapses in AIDS-related lymphomas
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